Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRA NASDAQ:KALV NASDAQ:MCRB NASDAQ:MEIP NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRABiofrontera$2.60$2.95$2.09▼$7.54$73.73M1.0227,512 shs7,263 shsKALVKalVista Pharmaceuticals$14.52-6.4%$12.55$7.30▼$16.32$721.93M-0.04571,330 shs2.09 million shsMCRBSeres Therapeutics$12.57+1.8%$8.45$6.53▼$30.60$109.74M2.75132,158 shs56,671 shsMEIPMEI Pharma$2.69$2.28$1.46▼$4.10$17.92M0.1944,175 shs11,204 shsOCULOcular Therapeutix$11.03-0.5%$8.36$5.79▼$11.78$1.76B1.431.44 million shs2.13 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRABiofrontera0.00%0.00%0.00%0.00%0.00%KALVKalVista Pharmaceuticals-3.00%+30.34%+9.15%+34.99%+23.39%MCRBSeres Therapeutics-0.24%+8.76%+49.52%+4.57%-37.42%MEIPMEI Pharma-2.18%-5.11%+16.96%+43.85%-3.58%OCULOcular Therapeutix+2.97%+18.38%+24.35%+55.84%+54.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRABiofronteraN/AN/AN/AN/AN/AN/AN/AN/AKALVKalVista Pharmaceuticals4.1595 of 5 stars3.61.00.04.43.11.70.6MCRBSeres Therapeutics3.5901 of 5 stars2.92.00.04.62.80.80.0MEIPMEI Pharma1.9175 of 5 stars0.05.00.04.20.00.81.3OCULOcular Therapeutix3.9212 of 5 stars3.51.00.04.12.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRABiofrontera 0.00N/AN/AN/AKALVKalVista Pharmaceuticals 3.11Buy$26.2981.03% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67486.05% UpsideMEIPMEI Pharma 2.00HoldN/AN/AOCULOcular Therapeutix 3.00Buy$17.3357.15% UpsideCurrent Analyst Ratings BreakdownLatest OCUL, KALV, BFRA, MCRB, and MEIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025KALVKalVista PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$19.00 ➝ $27.007/8/2025KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $27.007/7/2025KALVKalVista PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$18.00 ➝ $20.005/29/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.005/6/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRABiofrontera$36.19M2.04N/AN/A$0.35 per share7.43KALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.86 per shareN/AMCRBSeres Therapeutics$126.32M0.87N/AN/A$1.61 per share7.81MEIPMEI PharmaN/AN/A$5.85 per share0.46$4.96 per shareN/AOCULOcular Therapeutix$63.72M27.58N/AN/A$2.01 per share5.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRABiofrontera-$14.88M-$0.73N/A∞N/A-59.44%-93.31%-24.02%N/AKALVKalVista Pharmaceuticals-$126.64M-$3.72N/AN/AN/AN/A-104.25%-78.69%9/4/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/12/2025 (Estimated)MEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%9/17/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.15N/AN/AN/A-323.09%-59.92%-41.98%8/6/2025 (Estimated)Latest OCUL, KALV, BFRA, MCRB, and MEIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025OCULOcular Therapeutix-$0.35N/AN/AN/A$13.12 millionN/A7/10/2025Q4 2025KALVKalVista Pharmaceuticals-$0.83-$3.69-$2.86-$0.99$4.20 millionN/A5/13/2025Q3 2025MEIPMEI PharmaN/A-$0.39N/A-$0.39N/AN/A5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRABiofronteraN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRABiofrontera0.131.261.13KALVKalVista PharmaceuticalsN/A10.4410.44MCRBSeres TherapeuticsN/A2.112.11MEIPMEI PharmaN/A16.7816.78OCULOcular Therapeutix0.2610.2210.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRABiofrontera60.07%KALVKalVista PharmaceuticalsN/AMCRBSeres Therapeutics59.34%MEIPMEI Pharma52.38%OCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipBFRABiofronteraN/AKALVKalVista Pharmaceuticals10.50%MCRBSeres Therapeutics4.70%MEIPMEI Pharma3.12%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRABiofrontera13828.36 millionN/ANot OptionableKALVKalVista Pharmaceuticals10049.72 million44.50 millionOptionableMCRBSeres Therapeutics3308.73 million8.32 millionOptionableMEIPMEI Pharma1006.66 millionN/AOptionableOCULOcular Therapeutix230159.30 million155.64 millionOptionableOCUL, KALV, BFRA, MCRB, and MEIP HeadlinesRecent News About These CompaniesOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Recommendation of "Buy" from AnalystsJuly 10 at 2:37 AM | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Up 5.5% - Here's What HappenedJuly 8 at 12:39 PM | marketbeat.com847,468 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Peregrine Capital Management LLCJuly 1, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Stock Price Up 7.7% - What's Next?June 30, 2025 | marketbeat.comOcular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? - NasdaqJune 27, 2025 | nasdaq.comOcular Therapeutix sharpens focus with retina-centric rebrandJune 27, 2025 | fiercepharma.comFOcular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused CompanyJune 26, 2025 | finance.yahoo.comOcular Therapeutixâ„¢ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused CompanyJune 26, 2025 | globenewswire.comOcular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?June 25, 2025 | zacks.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Up - Here's WhyJune 24, 2025 | marketbeat.comDeltec Asset Management LLC Has $19.91 Million Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)June 21, 2025 | marketbeat.comOcular Therapeutix to present at Clinical Trials at the Summit 2025June 18, 2025 | ophthalmologytimes.comOOcular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three yearsJune 17, 2025 | uk.finance.yahoo.comAssenagon Asset Management S.A. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)June 17, 2025 | marketbeat.comOcular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025June 16, 2025 | globenewswire.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from BrokeragesJune 15, 2025 | marketbeat.comQ&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trialJune 11, 2025 | ophthalmologytimes.comOOcular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMDJune 2, 2025 | ophthalmologytimes.comOH.C. Wainwright maintains $15 target on Ocular Therapeutix stockMay 31, 2025 | investing.comDemystifying Ocular Therapeutix: Insights From 7 Analyst ReviewsMay 29, 2025 | benzinga.comOcular Therapeutix chief scientific officer sells $21,712 in stockMay 29, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCUL, KALV, BFRA, MCRB, and MEIP Company DescriptionsBiofrontera NASDAQ:BFRABiofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.KalVista Pharmaceuticals NASDAQ:KALV$14.52 -0.99 (-6.38%) Closing price 04:00 PM EasternExtended Trading$14.24 -0.28 (-1.93%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Seres Therapeutics NASDAQ:MCRB$12.57 +0.22 (+1.78%) Closing price 04:00 PM EasternExtended Trading$12.56 -0.02 (-0.12%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.MEI Pharma NASDAQ:MEIP$2.69 0.00 (0.00%) Closing price 03:51 PM EasternExtended Trading$2.65 -0.04 (-1.49%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Ocular Therapeutix NASDAQ:OCUL$11.03 -0.05 (-0.45%) Closing price 04:00 PM EasternExtended Trading$11.08 +0.04 (+0.41%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
